RT Journal Article
SR Electronic
T1 Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.05.22277210
DO 10.1101/2022.07.05.22277210
A1 Corominas, Júlia
A1 Garriga, Carme
A1 Prenafeta, Antoni
A1 Moros, Alexandra
A1 Cañete, Manuel
A1 Barreiro, Antonio
A1 González-González, Luis
A1 Madrenas, Laia
A1 Güell, Irina
A1 Clotet, Bonaventura
A1 Izquierdo-Useros, Nuria
A1 Raïch-Regué, Dàlia
A1 Gallemí, Marçal
A1 Blanco, Julià
A1 Pradenas, Edwards
A1 Trinité, Benjamin
A1 Prado, Julia G
A1 Blanch-Lombarte, Oscar
A1 Pérez-Caballero, Raúl
A1 Plana, Montserrat
A1 Esteban, Ignasi
A1 Pastor-Quiñones, Carmen
A1 Núñez-Costa, Xavier
A1 Taleb, Rachel Abu
A1 McSkimming, Paula
A1 Soriano, Alex
A1 Nava, Jocelyn
A1 Anagua, Jesse Omar
A1 Ramos, Rafel
A1 Lluch, Ruth Martí
A1 Comes, Aida Corpes
A1 Romero, Susana Otero
A1 Gomez, Xavier Martinez
A1 Sans-Pola, Carla
A1 Moltó, José
A1 Benet, Susana
A1 Bailón, Lucía
A1 Arribas, Jose R
A1 Borobia, Alberto M
A1 Parada, Javier Queiruga
A1 Navarro-Pérez, Jorge
A1 Forner Giner, Maria José
A1 Lucas, Rafael Ortí
A1 Vázquez Jiménez, María del Mar
A1 Compán, Salvador Oña
A1 Alvarez-Mon, Melchor
A1 Troncoso, Daniel
A1 Arana-Arri, Eunate
A1 Meijide, Susana
A1 Imaz-Ayo, Natale
A1 García, Patricia Muñoz
A1 de la Villa Martínez, Sofía
A1 Fernández, Sara Rodríguez
A1 Prat, Teresa
A1 Torroella, Èlia
A1 Ferrer, Laura
YR 2023
UL http://medrxiv.org/content/early/2023/03/02/2022.07.05.22277210.abstract
AB Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and welltolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration.Methods The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine —either heterologous (PHH-1V group) or homologous (BNT162b2 group)— in 10 centres in Spain. Eligible subjects were allocated to treatment stratified by age group (18-64 versus ≥65 years) with approximately 10% of the sample enrolled in the older age group. The primary endpoints were humoral immunogenicity measured by changes in levels of neutralizing antibodies (PBNA) against the ancestral Wuhan-Hu-1 strain after the PHH-1V or the BNT162b2 boost, and the safety and tolerability of PHH-1V as a boost. The secondary endpoints were to compare changes in levels of neutralizing antibodies against different variants of SARS-CoV-2 and the T-cell responses towards the SARS-CoV-2 spike glycoprotein peptides. The exploratory endpoint was to assess the number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster. This study is ongoing and is registered with ClinicalTrials.gov, NCT05142553.Findings From 15 November 2021, 782 adults were randomly assigned to PHH-1V (n=522) or BNT162b2 (n=260) boost vaccine groups. The geometric mean titre (GMT) ratio of neutralizing antibodies on days 14, 28 and 98, shown as BNT162b2 active control versus PHH-1V, was, respectively, 1·68 (p<0·0001), 1·31 (p=0·0007) and 0·86 (p=0·40) for the ancestral Wuhan-Hu-1 strain; 0·62 (p<0·0001), 0·65 (p<0·0001) and 0·56 (p=0·003) for the Beta variant; 1·01 (p=0·92), 0·88 (p=0·11) and 0·52 (p=0·0003) for the Delta variant; and 0·59 (p=<0·0001), 0·66 (p<0·0001) and 0·57 (p=0·0028) for the Omicron BA.1 variant. Additionally, PHH-1V as a booster dose induced a significant increase of CD4+ and CD8+ T-cells expressing IFN-γ on day 14. There were 458 participants who experienced at least one adverse event (89·3%) in the PHH-1V and 238 (94·4%) in the BNT162b2 group. The most frequent adverse events were injection site pain (79·7% and 89·3%), fatigue (27·5% and 42·1%) and headache (31·2 and 40·1%) for the PHH-1V and the BNT162b2 groups, respectively. A total of 52 COVID-19 cases occurred from day 14 post-vaccination (10·14%) for the PHH-1V group and 30 (11·90%) for the BNT162b2 group (p=0·45), and none of the subjects developed severe COVID-19.Interpretation Our interim results from the Phase IIb HH-2 trial show that PHH-1V as a heterologous booster vaccine, when compared to BNT162b2, although it does not reach a non-inferior neutralizing antibody response against the Wuhan-Hu-1 strain at days 14 and 28 after vaccination, it does so at day 98. PHH-1V as a heterologous booster elicits a superior neutralizing antibody response against the previous circulating Beta and the currently circulating Omicron BA.1 SARS-CoV-2 variants in all time points assessed, and for the Delta variant on day 98 as well. Moreover, the PHH-1V boost also induces a strong and balanced T-cell response. Concerning the safety profile, subjects in the PHH-1V group report significantly fewer adverse events than those in the BNT162b2 group, most of mild intensity, and both vaccine groups present comparable COVID-19 breakthrough cases, none of them severe.Funding HIPRA SCIENTIFIC, S.L.U.Competing Interest StatementThe authors of this manuscript declare: J Blanco has received institutional grants from HIPRA, Grifols, and MSD, royalties for licensed patent from AlbaJuna, honoraria for lectures from FLS Science and CIBER, supporting for meeting and/or travel from Gilead, and unpaid independent COVID-19 monitoring from GMCSC (Multidisciplinary Collaborative Group for the Scientific Monitoring of COVID-19) and unpaid participation in COVID-19 advisory group for CCAC (Comite Cientific Assessor de la COVID-19). Outside of this work, J Blanco is the CEO, founder and shareholder of AlbaJuna Therapeutics, S.L. J Corominas, C Garriga, A Barreiro, L Gonzalez-Gonzalez, L Madrenas, I Guell, D Raich-Regue, J G Prado, T Prat, E Torroella, B Trinite, L Ferrer, M Canete and A Prenafeta have received funding from HIPRA. The funding from HIPRA to R Ramos was paid to his institution. A Soriano has received grants from Pfizer and Gilead Sciences, consulting fees from Pfizer, MSD and Shionogi, and honoraria for lectures for Pfizer, MSD, Gilead Sciences, Shionogi, Angelini, and Menarini. B Trinite declares royalties by an institutional agreement and consulting fees for HIPRA, and is an unpaid member in advisory board for the Health Department of the Generalitat de Catalunya. N Izquierdo-Useros, D Raich-Regue and M Gallemi declare institutional grants from HIPRA, Pharma Mar, Grifols, Dentaid, Palobiofarma, Mynorix and Amassence. N Izquierdo-Useros and M Gallemi have received speaking honoraria from FLS Science. JR Arribas has received consulting fees and payment for participating in advisory board from Gilead Sciences, MSD, GSK, Eli Lilly, Roche, Pfizer and Sobi, honoraria for lectures and support for meetings and/or travel from MSD. A Borobia has received grants from GSK, Moderna and Janssen, speaking honoraria for Janssen, Gilead Sciences and Pfizer, and payment for participating in advisory board for Pfizer, Janssen and MDI. PM Garcia has received consulting fees and speaking honoraria from Gilead Sciences, Mundipharma and Pfizer, payment for expert testimony and participated in advisory board for Gilead Sciences and received support for meeting and/or travel from Pfizer. S Otero-Romero has received speaking honoraria from Genzyme, Biogen-Idec, Novartis, Roche, and MSD. Julia G Prado declares institutional grants from Grifols.J Corominas, C Garriga, A Prenafeta, A Moros, M Canete, A Barreiro, L Gonzalez-Gonzalez, L Madrenas, I Guell, T Prat, E Torroella and L Ferrer are employees of HIPRA. Some of these authors may have stocks of HIPRA.Several patent applications have been filed by HIPRA SCIENTIFIC S.L.U. and Laboratorios HIPRA, S.A. on different SARS-CoV-2 vaccine candidates and SARS-CoV-2 subunit vaccines, including the novel recombinant RBD fusion heterodimer PHH-1V. A Barreiro, J Corominas, A Prenafeta, L Gonzalez-Gonzalez, L Madrenas, L Ferrer, E Torroella, T Prat and C Garriga are the inventors of these patent applications. N Izquierdo-Useros is a patent inventor with no economical compensation for Pharma Mar and Mynorix.The other authors have no relevant conflicts of interest to declare.Clinical TrialNCT05142553Funding StatementThis work was supported by HIPRA SCIENTIFIC, S.L.U (HIPRA) and partially funded by the Centre for the Development of Industrial Technology (CDTI, IDI-20211192), a public organisation answering to the Spanish Ministry of Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted in accordance with the Declaration of Helsinki, the Good Clinical Practice guidelines, and national regulations. The study protocol was reviewed and approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) as well as Independent Ethics Committee from the Hospital Clinic de Barcelona. Written informed consent was obtained from all participants before enrolment. The biologic biosafety committee of the Research Institute Germans Trias and Pujol approved the execution of SARS-CoV-2 experiments at the BSL3 laboratory of the Centre for Bioimaging and Comparative Medicine (CSB-20-015-M8).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary information. Further data are available from the authors upon reasonable request and with permission of HIPRA S.A.